SCD-HeFT update
This article was originally published in The Gray Sheet
Executive Summary
CMS will "undertake a complete review of the available literature" on prophylactic implantation of ICDs in patients with poor ventricular function, including SCD-HeFT, DINAMIT, DEFINITE and COMPANION clinical trials, CMS announces March 30. The agency also will assess evidence pertaining to selection of appropriate defibrillators for specific patient populations. The review responds to 1Medtronic's March 18 request that CMS amend its ICD coverage policy to include all patients with at least one year of remaining life expectancy, documented congestive heart failure for greater than 3 months and left-ventricular function of less than 35% - the indication evaluated in the SCD-HeFT trial. Following release of CMS' ICD coverage policy in 2003, the agency agreed to revisit its coverage criteria once SCD-HeFT results were unveiled (2"The Gray Sheet" March 15, 2003, p. 3)...
You may also be interested in...
CMS Welcomes SCD-HeFT Data, Awaits COMPANION Study For ICD Review
CMS plans to integrate Guidant's COMPANION study findings with recently released data from the SCD-HeFT trial to make a decision on whether to redefine the patient population eligible for ICD coverage
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.